Review article: percutaneous treatment of hepatocellular carcinoma
|
|
- Julie Atkins
- 8 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 2003; 17 (Suppl. 2): Review article: percutaneous treatment of hepatocellular carcinoma S. GAIANI, N. CELLI, L. CECILIONI, F. PISCAGLIA & L. BOLONDI Dipartimento di Medicina Interna e Gastroenterologia, Università di Bologna, Italy SUMMARY In early stage hepatocellular carcinoma (HCC), liver transplantation, surgical resection and percutaneous techniques are classified as radical treatments, and may be offered to about 25% of all patients with HCC evaluated in referral centres. The restricted inclusion criteria for surgical resection and the shortage of liver donors for transplantation have stimulated an increasing demand for minimally invasive treatments able to achieve effective and reproducible percutaneous tumour ablation, with less associated morbidity and lower cost than other interventions. Among percutaneous techniques, ethanol injection has proven to be highly effective in single HCC up to 3 cm, with a rate of complete response of 80%, being well tolerated and with a limited risk of minor complication. In larger and or multinodular HCC the efficacy is reduced to 50% of complete response in nodules between 3 and 5 cm, and to lower rate in larger tumours. Alternative options to ethanol injection have been recently proposed, including radiofrequency, microwave and laser thermal ablation, aimed to extend the necrotic area thus improving the rate of complete response. To date, radiofrequency is the most used technique, with a reported rate of complete response of 90 98% in nodules smaller than 3 cm, and with the advantage of fewer sessions, otherwise counteracted by a higher rate of side-effects. Microwave and laser are promising technologies, but only few clinical data are available. Randomized controlled trials are needed in order to assess treatment response, long-term survival, rate of complication and cost-efficacy of newer technologies in comparison to ethanol injection. INTRODUCTION The incidence of hepatocellular carcinoma (HCC) is increasing world-wide, being the fifth most common cancer in the world (over cases year) and the third cause of cancer-related death. 1, 2 Striking geographical differences are observed for both risk factors and occurrence. Cirrhosis, mainly caused by hepatitis B and C viruses, constitutes the main risk factor for HCC, with the 5-year cumulative incidence ranging between 15% and 20%. 3 In Italy and in other areas with intermediate incidence of HCC (5 20 cases per inhabitants) HCC is associated with liver cirrhosis in more than 90% of cases. Cirrhotic men with increased a-fetoprotein (AFP) concentration bear the highest risk. Correspondence to: Dr S. Gaiani, Dipartimento di Medicina Interna e Gastroenterologia, Università di Bologna via Albertoni 15, Bologna, Italy. sgaiani@med.unibo.it Surveillance is the sole strategy to potentially decrease tumour related mortality because it may detect HCC at an early stage, when curative therapies can be applied. 4 The available data on tumour volume doubling time provide the rationale for the current recommended surveillance policy: ultrasound (US) and AFP determination every 6 months. 3 By applying this policy, 40 80% of HCCs detected are solitary, but only half of them are radically treated. 5, 6 The main factors affecting prognosis include: the stage, aggressiveness and growth rate of the tumour, the general health of the patient, the liver function and the specific therapeutic intervention. BACKGROUND The treatment decision should be based on the tumour stage at diagnosis and the degree of impairment of liver function as a result of the underlying cirrhosis. As Ó 2003 Copyright Blackwell Publishing Ltd 103
2 104 S. GAIANI et al. recently stated in the Barcelona EASL Conference, surgical resection, liver transplantation and percutaneous ablation techniques should be considered radical treatments for early stage HCC, because they achieve a high rate of complete response in properly selected candidates thus improving the natural history of the disease and prolonging the survival of patients with single HCC smaller than 5 cm or three nodules smaller than 3 cm. 3 Surgical resection and liver transplantation are considered the first line options, although the best treatment strategy has not been established. Liver transplantation is claimed to simultaneously cure the tumour and the underlying cirrhosis in well-selected patients and is therefore presented as the optimal treatment. 7 Properly selected candidates for liver transplantation achieve a 70% 5-year survival rate with a recurrence rate below 25% This theoretical superiority, however, is dampened by the severe shortage of liver donors, and the progressively increasing waiting time deteriorates the results of liver transplantation when analysed according to intention-to-treat. Surgical resection provides excellent results for solitary HCC in patients with preserved liver function (Child class A). Five-year survival in well-selected patients with resectable HCC is approximately 50%, 11, 12 reaching a 70% rate in those with normal bilirubin concentration and without portal hypertension. 13 Surgical resection for HCC is affected by a high recurrence rate, as compared with liver transplantation, that may exceed 50% at 3 years and 70% at 5 years, 12, 14, 15 due to the multifocal nature of the disease. In clinical practice, only 20 30% of all the HCC patients currently evaluated in referral centres may receive radical treatment for early stage tumours. 7 PERCUTANEOUS TREATMENT Percutaneous treatment of HCC, initially proposed in patients where surgery was contraindicated, has now become an alternative choice to surgery. The rationale for the use of percutaneous ablation techniques of HCC is based on some relevant advantages: to destroy the tumour avoiding the loss or the damage of nontumoral liver parenchyma, as occurs with resection and arterial chemoembolization; the low risk of complication associated with the procedure, with 16, 17 a mortality rate of % for ethanol injection; the possibility to easily repeat the treatment in case of recurrent lesions, which develop in the majority of patients within 5 years; and finally, to be easy available and relatively inexpensive, considering that the cost of an alcohol injection cicle is about 1000 US dollars, compared with a cost of over US dollars for liver 18, 19 resection. ETHANOL INJECTION In the last decade, the most extensive clinical experience has been based on percutaneous ethanol injection (PEI), which has become very popular as a result of the combination of low cost and a high antitumoral efficacy in small solitary tumours. The mechanism of action of ethanol depends on its ability to penetrate the tumoral cells, producing coagulative necrosis as a consequence of deydratation of cytoplasmic proteins. In addition, ethanol causes the thrombosis of tumoral microcirculation, as a result of necrosis of endothelial cells and platelet aggregation, with consequent ischaemia of the neoplastic tissue. The toxic action of ethanol is facilitated by the pathological features of HCC such as hypervascularity, which favours its uniform distribution within the nodule, and the softer consistency of the tumour in comparison to the surrounding cirrhotic parenchyma, which allows an easy and selective diffusion of the injected ethanol. PEI has proven to be highly effective in single HCC up to 3 cm, obtaining a complete response in 80% of cases, 20 being well tolerated and with a limited risk of minor complication. In larger and or multinodular HCC the efficacy is reduced to 50% of complete response in nodules between 3 and 5 cm, and to a lower rate in larger tumours. The size of the tumour also influences the rate of local recurrence. 16 The decreased efficacy in the treatment of large tumours and continuous multinodular HCC is due to intratumoral septa that limits ethanol diffusion and prevents homogeneous distribution throughout the tumour. Also, multiple treatment sessions, which lead to a prolonged treatment period, may increase the chance of tumour cell seeding. 16 Long-term efficacy of PEI has been reported in several studies (Table 1). In the study by Ebara et al. on 95 patients with 120 HCC smaller than 3 cm, 1-, 3- and 5- year survival was, respectively, 96, 72 and 51% for patients with Child A; 90, 62 and 48% for Child B; and 94, 25 and 0% for patients with Child C cirrhosis. 21 Shiina et al. studied a series of 50 patients including
3 REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA 105 Table 1. Reported outcomes in patients with HCC treated by percutaneous ethanol injection (PEI) HCC up to 6 cm in size, reporting a 1-, 3- and 5-year survival of 87, 62 and 43%. 22 In a group of 70 selected patients with compensated cirrhosis and single HCC smaller than 3 cm, Lencioni et al. reported a 3- and 5-year survival of 89 and 67%, respectively. 23 In a multicentric Italian study, 1-, 3- and 5-year survival in patients with single HCC smaller than 5 cm was, respectively, 98, 79 and 47% (293 patients in Child A), 93, 63 and 29% (149 patients in Child B), and 64, 12 and 0% (20 patients in Child C). 16 Similar results were reported in the nationwide survey in Japan, 24 with 1- and 5-year survival of 96% and 54% in HCC smaller than 2 cm, and 95% and 38% in HCC 2 5 cm in size in stage I patients; 92% and 33% in HCC smaller than 2 cm, and 87% and 28% in HCC 2 5 cm in stage II patients. The long-term outcome after PEI is characterized by a high recurrence rate, ranging from 64% to 98% at 5 years 16, being higher in multifocal HCC, while local recurrence rates ranged from 4% in lesions smaller than 3 cm 21 to 17% in lesions of 3 5 cm. 16 Other than the size of the tumour and multifocality, increased rate n Survival (%) 3 years 5 years Ebara et al Child A Child B Child C 25 0 Shiina et al Lencioni et al. 23 Child A HCC 3cm Child A, HCC 3cm Livraghi et al. 16 Child A Child B Child C Arii et al. 12 Stage I, HCC < 2 cm Stage I, HCC 2 5 cm Stage II, HCC < 2 cm Stage II, HCC 2 5 cm Livraghi et al. 26 Large encapsulated HCC (> 5 cm) 57 Large infiltrating HCC (> 5 cm) 42 of recurrence is dependant on the tightly related pathological features, such as poor differentiation degree, vascular invasion and satellites. In the case of intermediate HCC, conventional PEI may require an exceedingly high number of sessions, thus prolonging the period of treatment and increasing the risk of complications related to repeated needle insertions. Livraghi et al. proposed the injection of a large volume of ethanol (up to ml) in a single session, performed under general anaesthesia. 25 Using this technique, a 3-year survival of 57% and 42% was obtained, respectively, in encapsulated and infiltrating HCC larger than 5 cm. 26 A combination of transarterial embolization with PEI has been proposed on the assumption that ischaemia induced by arterial obstruction could destroy the intratumoral septa and facilitate the diffusion of ethanol. Some encouraging reports have described a relatively high complete response rate and 3- and 5-year survival 27, 28 of % and 59 75% in Child class A patients. The long-term benefits of this approach have been recently assessed within a randomized controlled study. 29 The combination therapy with transarterial embolization-pei was superior to PEI alone in terms of local residual disease and recurrence rates in a series of 52 patients with small HCC (<3 cm). The survival rate was higher for the combination therapy in the subgroup of patients with nodules smaller than 2 cm, while the cumulative survival rates did not significantly differ between the two groups. An alternative approach to ethanol injection is to use other agents with a higher diffusion capacity, such as acetic acid. A randomized trial reported that the injection of acetic acid provided better results in terms of local efficacy, recurrence rate and survival in comparison with PEI. These promising results, however, have been achieved by only one group in Japan, and their results using PEI were less than optimal. 30 THERMAL ABLATION In recent years, many efforts have been made to investigate alternative percutaneous treatment modalities of HCC, able to increase the rate of complete response while maintaining the same safety of PEI. These include the use of energies able to produce a thermal ablation of tumoral cells, such as radiofrequency, microwave and laser. To date, other techniques
4 106 S. GAIANI et al. such as cryotherapy and high-intensity focused ultrasound are confined to experimental studies. The main aim of thermal ablation therapy is to destroy the entire tumour by using heat to kill malignant cells in a minimally invasive fashion, without damaging adjacent vital structures. Independently from the source of energy used to produce the thermal ablation, the heat cells interaction is strictly dependant on the temperature reached and the exposure time. Cellular homeostasis can be maintained with mild elevation of temperature to 40 C, while at temperatures between 42 C and 45 C, cells experience an increased susceptibility to damage produced by other agents such as chemotherapy and radiation. Higher temperatures, between 46 C and 60 C, are associated with irreversible cellular damage that is proportional to the exposure time; between 60 C and 100 C, a nearly instantaneous induction of protein coagulation occurs, with irreversible damage of key cytosolic and mitochondrial enzymes and nucleic acidhistone complexes. Temperatures greater than 105 C result in tissue boiling, vaporization and carbonization. These processes increase the impedance of the tumoral tissue surrounding the needle tip electrode, thus decreasing the energy transmission deepening into the tissue and the consequent ablation volume. Thus, the key aim for thermal ablative therapies is achieving and maintaining a C temperature range throughout the entire target volume. Multiple energy sources have been used to provide the thermal induced coagulation necrosis, and electromagnetic energy has been used in the form of both radiofrequency and microwaves. RADIOFREQUENCY THERMAL ABLATION To date, the interest and enthusiasm for radiofrequency thermal ablation has far exceeded that for either microwave or laser ablation, and the largest clinical experience has been based in the last years on this ablation technique. The radiofrequency ablation system uses wave frequencies of KHz, and the energy is delivered to the tumour by an needle electrode (16 18 gauge) that is electrically insulated along all but the distal 1 3 cm of the shaft. Radiofrequency emanates from the exposed noninsulated portion of the electrode. This energy, as it attempts to reach a grounding pad (placed on the patient s back or thigh), is converted into heat, inducing cellular death through coagulation necrosis. Until recently, an important limitation of percutaneous thermal ablation techniques was the extent of the volume of coagulation produced in a single session treatment, and a major focus of research has been the improvement of radiofrequency technology to enable an increase in the size of coagulation necrosis. Expandable electrode needles increase the radiating surface by an array of multiple wires that expand from the needle tip after insertion within the tumour. Cooled-tip electrodes consist of dual-lumen needles, with an internal lumen through which 0 C saline is circulated. 31 This prevents tissue boiling and cavitation immediately adjacent to the needle tip, thus increasing generator output during radiofrequency application. Electrodes can be inserted either singly or as a cluster array of three electrodes 32, 33 spaced 0.5 cm apart. These techniques offer the potential of large volume coagulation necrosis produced with a single needle insertion. The uniformity and reproducibility of thermal lesions with two different ablation devices were compared in explanted calf liver and in vivo pig liver. 34 The triple cluster cooled-tip needle induced significantly larger lesions than the expandable needle, but the lesions produced by the expandable needle were more reproducible and uniform in shape. Despite the lack of comparative studies in humans, both devices are currently used in clinical practice with similar results in terms of extent of necrosis (Table 2). The results from preliminary clinical series suggest that radiofrequency ablation is promising for the Table 2. Clinical studies on percutaneous radiofrequency thermal ablation in patients with HCC n Size Needle Sessions Complete response Rossi et al Exp (100%) Livraghi et al Cool (90%) Lencioni et al Exp cool (95%) Curley et al Exp (98%) Curley et al Exp (97%) Livraghi et al Cool (61%) Cool (24%) exp ¼ expandable needle; cool ¼ cooled-tip needle.
5 REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA 107 treatment of hepatic tumours, although the long-term clinical benefits remain relatively unproved, because of the relatively short follow-up period (Table 2). Rossi et al. 35 treated 39 patients with 41 HCC, all but one being smaller than 3 cm, with a monopolar and bipolar needle. With a mean of 3.3 treatment session, a recurrence rate of 41% was observed at a mean followup of 22 months. Subsequently, Rossi et al. 36 reported the results obtained in 23 patients with 26 HCC of cm in size using an expandable needle that reduced the number of sessions to 1.4 per tumour. They obtained a complete response of 100%, with a recurrence rate of 29% at 10 months. Other studies report a rate of complete response ranging from 90% to 98% in small HCC (< 3 cm), using both the cooled-tip and the expandable needle Ethanol injection remains the standard percutaneous technique for small HCC, therefore the results of new ablation techniques should be compared with that of PEI. Livraghi et al. 37 compared radiofrequency with PEI in 86 patients with 112 HCC ( 3 cm) reporting a rate of complete necrosis of 90.3% after radiofrequency and of 80% after PEI, without reaching statistical significance. Treatment with radiofrequency required significantly fewer sessions than did treatment with PEI (1.2 vs. 4.8), while more complications were observed with radiofrequency than with PEI. Similar results were reported in a randomized trial by Lencioni et al. in 80 patients with 115 HCC ( 3 cm), with a rate of complete response of 91% for radiofrequency and 85% for PEI, and with a longterm control in 87% of lesions treated with radiofrequency in comparison with 70% of lesions treated with PEI. 38 In a third study complete tumour ablation was obtained in 100% of 23 HCC treated with radiofrequency and in 94% of 96 HCC treated with Table 3. Comparison of percutaneous ethanol injection (PEI) and radiofrequency (RF) thermal ablation in patients with small HCC ( 3 cm) n Sessions Complete response (%) PEI RF PEI RF Livraghi et al Lencioni et al. 38 * Ikeda et al *Randomized trial. PEI, with a local recurrence rate at 1 year of 15% and 14%, respectively, 41 (Table 3). Worse results are expected in the treatment of recurrent HCC, accordingly to the more aggressive biological behaviour of the tumour over time. Preliminary data report that recurrence after radiofrequency ablation is higher in patients treated for recurrent HCC than in patients treated for HCC at the first diagnosis. 42 Treatment of large tumours is still problematic. Livraghi et al. 43 treated 114 patients with 126 nodules of HCC greater than 3 cm (mean 5.4 cm), achieving a complete response in 61% of HCC < 5 cm and of 24% of nodules 5 cm. Noninfiltrating tumours were treated successfully significantly more often than infiltrating tumours. As a consequence, there is currently a focus on a multimodal strategy to ensure a more effective treatment of large tumour nodules. Rossi et al. 44 treated 62 patients with HCC nodules of cm in diameter with radiofrequency sessions after occlusion of either the hepatic artery with a balloon catheter or the feeding arteries with gelatin sponge particles. The 1-year local recurrence rate was 18%, while the overall intrahepatic recurrence was 48%. A relatively high rate of complications have been reported with radiofrequency thermal ablation, including tumoral dissemination in the case of subcapsular HCC. 45 This risk may be greatly reduced by proper selection criteria with the exclusion of those nodules that cannot be reached through a path of liver tissue. 46 Proximity with the gall-bladder or with large intrahepatic vessels are other factors that may contraindicate radiofrequency thermal ablation. On the other hand, a recent multicentre study including 1620 patients with HCC treated by radiofrequency ablation reports a low risk of major complications (2.1%), with 0.25% of death and 0.49% of tumoral seeding. 47 MICROWAVE THERMAL ABLATION Microwave thermal tissue coagulator emits 2450 MHz electromagnetic radiation. Its mechanism of heating is similar to that of radiofrequency. The electrode inside the tissue acts as an antenna, concentrating a high intensity electromagnetic field with polarization of the molecules and consequent tissue heating. The technique has been used in few clinical studies. Seki et al. 48 treated 18 HCC < 2 cm with one to four sessions, with complete response and recurrence in three out of 18
6 108 S. GAIANI et al. cases at months. Recently, a larger series has been published, including 50 patients with 107 HCC (mean size 2.7 cm) treated with single or multiple microwave sessions. Complete necrosis was attained in 98% of nodules < 2 cm and in 92% of nodules > 2 cm, with a recurrence rate at 1 year of 45%. 49 Microwave ablation has been retrospectively compared with PEI in 90 HCC 2 cm, with similar results in terms of local response and overall 5-year survival (78% for PEI and 70% for microwave), while the survival was better for microwave than for PEI (78% vs. 35%) in the sub-group of poorly to moderately differentiated HCC. 50 Finally, microwave has been compared with radiofrequency ablation in a randomized controlled trial including 94 HCC of cm in size, reporting equiv alent therapeutic effects and complication rates, but fewer treatment sessions for radiofrequency. 51 With the available technology, microwave ablation seems to be effective in tumours 2 cm, but requires the insertion of multiple large needles (1.6 mm) and repeated treatment sessions in case of tumours > 2.5 cm in diameter. LASER THERMAL ABLATION Laser is a monochromatic, collimated and coherent radiation with a wavelength of 1024 nm produced by a Nd:YAG generator, which concentrates extremely high energy in small focalized areas. It may be transmitted inside the tumour by single or multiple quartz optical fibres inserted through fine needles (21 gauge), thus converting the intense light energy to tissue heating. Tumours cm can be treated with a single fibre, while larger nodules require the splitting of the laser beam with the insertion of multiple fibres (up to four) by gauge fine needles, whose precise positioning may be technically difficult. Laser ablation has been mainly used in the treatment of liver metastases, while very few data are available on the treatment of HCC. Giorgio et al. 52 treated 85 HCC of cm with one to four laser fibres inserted and single or multiple sessions, obtaining a complete necrosis in 82%. In the study of Pacella et al HCC 4 cm were treated with multiple fibre insertion, with an average of 1.3 sessions per tumour. Complete necrosis was obtained in 97%, while a mean follow-up of 25 months showed a local and elsewhere in the liver recurrence of 6% and 49%, respectively. The same investigators treated 30 large HCC ( cm) by laser thermal ablation followed by segmental transarterial embolization at days, obtaining complete tumour necrosis in 90%, with cancer-free survival rate at 1- and 2-years of 74% and 34%, respectively. 54 CONCLUSIONS Screening programmes based on ultrasound and AFP determination have substantially increased the proportion of solitary or paucifocal HCC that can be radically treated. The restricted inclusion criteria for surgical resection and the shortage of liver donors for transplantation have stimulated an increasing demand for percutaneous tumour ablation procedures, which have been demonstrated to be effective and safe, with less associated morbidity and lower cost than other interventions. Analysis of the published data demonstrates that the size of the tumour to be treated is the crucial factor in determining whether complete necrosis can be achieved. In general, lesions smaller than 2.5 cm in diameter have been reported to have a greater than 90% chance of being destroyed. For lesions measuring cm, approximately 70 90% may be completely treated with current ablation techniques, while the rate of complete response decreases for larger nodules. In such cases percutaneous techniques should be limited to those excluded by surgery, possibly in association with segmental transarterial embolization. To date, PEI should be considered the standard percutaneous technique, however radiofrequency ablation seems to produce at least similar results in terms of efficacy, with fewer sessions, otherwise counteracted by a relatively higher risk of complication. Future research should be focused on both technical and clinical issues. The former include: (a) the development of optimal ablation techniques that can increase the volume of tissue destroyed, (b) the identification of mechanisms that can integrate and enhance the ablation technique by haemodynamic and pharmacological agents, and (c) the development of new and less invasive thermal ablation modalities (i.e. extracorporeal high intensity focused ultrasound). Clinical issues for the future include: (a) the assessment of efficacy of multimodal and combined treatments, (b) the optimization of a properly selection of patients, and (c) the design of randomized controlled trials aimed to assess treatment response, long-term survival, rates of complication and cost-efficacy of newer technologies in comparison to ethanol injection.
7 REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA 109 REFERENCES 1 El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the united states. N Engl J Med 1999; 340: Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: GLOBOCAN Int J Cancer 2001; 94: Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of Barcelona-2000 EASL Conference. J Hepatol 2001; 35: Camma C, Giunta M, Andreone P, et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl Med 1991; 325: Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: Llovet JM, Fuster J, Bruix J, et al. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology 2001; 33: LCSG. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31: Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000; 32: Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31: Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: Di Stasi M, Buscarini L, Livraghi T, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma: a multicenter survey of evaluation practices and complications rates. Scand J Gastroenterol 1997; 32: Livraghi T. Guidelines for treatment of liver cancer. Eur J Ultrasound 2001; 13: Kotoh K, Sakai H, Sakamoto S, et al. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. Am J Gastroenterol 1994; 89: Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: Ebara M, Ohto M, Sugiura N, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 1990; 5: Shiina S, Tagawa K, Niwa Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. Am J Roentgenol 1993; 160: Lencioni R, Pinto F, Armillotta N, et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997; 7: Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group Japan Hepatol 2000; 32: Livraghi T, Lazzaroni S, Pellicano S, et al. Percutaneous ethanol injection of hepatic tumors: single-session therapy with general anesthesia. Am J Roentgenol 1993; 161: Livraghi T, Benedini V, Lazzaroni S, Meloni F, Torzilli G, Vettori C. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma. Cancer 1998; 83: Tanaka K, Nakamura S, Numata K, et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. Cancer 1998; 82: Lencioni R, Paolicchi A, Moretti M, et al. Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and long-term survival rate. Eur Radiol 1998; 8: Koda M, Murawaki Y, Mitsuda A, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 2001; 92: Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998; 27: Goldberg SN, Gazelle GS, Halpern EF, et al. Radiofrequency tissue ablation: importance of local temperature along the electrode tip exposure in determining lesion size and shape. Acad Radiol 1996; 3: Lorentzen T, Christensen NE, Nolsoe CP, et al. Radiofrequency tissue ablation with cooled needle in vitro: ultrasonography,
8 110 S. GAIANI et al. dose response, and lesion temperature. Acad Radiol 1997; 4: Goldberg SN, Sobiati L, Hahn PF, et al. Radiofrequency tumor ablation using a clustered electrode technique: results in animals and patients with liver metastases. Radiology 1998; 209: de Baere T, Denys A, Wood BJ, et al. Radiofrequency liver ablation: experimental comparative study of water-cooled versus expandable systems. Am J Roentgenol 2001; 176: Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am J Roentgenol 1996; 167: Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumours by an expandable RF needle electrode. Am J Roentgenol 1998; 170: Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology 1999; 210: Lencioni R, Cioni D, Donati F, et al. Percutaneous treatment of small hepatocellular carcinoma in cirrhosis: Rf thermal ablation vs. PEI. A prospecctive randomized trial. Radiology 1999; 213: Curley SA, Izzo F, Delria P, et al. Radiofrequency ablation of unresectable primary ad metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999; 230: Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232: Ikeda M, Okada S, Ueno H, Okusaka T, Kuriyama H. Radiofrequency ablation and percutaneous ethanol injection in patients with small hepatocellular carcinoma: a comparative study. Jpn J Clin Oncol 2001; 31: Gaiani S, Piscaglia F, Celli N, et al. Percutaneous radio-frequency thermal ablation of hepatocellular carcinoma. Results and follow-up in primary and recurrent nodules. Hepatology 2001; 34: Livraghi T, Meloni F, Goldberg SN, et al. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 2000; 214: Rossi S, Garbagnati F, Lencioni R, et al. Unresectable hepatocellular carcinoma: percutaneous radiofrequency thermal ablation after occlusion of tumor blood supply. Radiology 2000; 217: Llovet JM, Vilana R, Bru C, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33: Bolondi L, Gaiani S, Celli N, et al. Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. Hepatology 2001; 34: Livraghi T, Solbiati L, Meloni F, et al. Percutaneous radiofrequency ablation: complication encountered in a multicenter study of the treatment of focal liver tumors. Radiology 2003; 226: Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994; 74: Lu MD, Chen JW, Xie XY, et al. Hepatocellular carcinoma: US-guided percutaneous microwave coagulation therapy. Radiology 2001; 221: Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. Cancer 1999; 85: Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002; 223: Giorgio A, Tarantino L, de Stefano G, et al. Interstitial laser photocoagulation under ultrasound guidance of liver tumors: results in 104 treated patients. Eur J Ultrasound 2000; 11: Pacella CM, Bizzarri G, Magnolfi F, et al. Laser thermal ablation in the treatment of small hepatocellular carcinoma: results in 74 patients. Radiology 2001; 221: Pacella CM, Bizzarri G, Cecconi P, et al. Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology 2001; 219:
Surveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL HEPATOCELLULAR CARCINOMA GI Site Group Hepatocellular Carcinoma Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION
More informationHepatocellular Carcinoma Treatment Decision Tree
Treatment Decision Tree Derek DuBay, MD Assistant Professor of Surgery Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery 1 UAB Liver Tumor Clinic Referrals: 205 996 5970 (phone) 205
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microwave_tumor_ablation 12/2011 11/2015 11/2016 11/2015 Description of Procedure or Service Microwave ablation
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationHEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION. Francis Yao, M.D.
UCSF TRANSPLANT CONFERENCE - 9/28/2012 HEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation
More informationHepatocellular Carcinoma Management Guidelines
Hepatocellular Carcinoma Management Guidelines By Ashraf Omar M.D, Prof. of Hepatology & Tropical Medicine Cairo University Staging Strategy and Treatment for Patients With HCC HCC PST 0, Child-Pugh A
More informationHepatocellular Carcinoma: What the hepatologist wants to know
Hepatocellular Carcinoma: What the hepatologist wants to know Hélène Castel, MD Liver Unit Hôpital St-Luc CHUM? CAR Annual Scientific Meeting Saturday, April 27 th 2013 Disclosure statement I do not have
More informationA PATIENT S GUIDE TO ABLATION THERAPY
A PATIENT S GUIDE TO ABLATION THERAPY THE DIVISION OF VASCULAR/INTERVENTIONAL RADIOLOGY THE ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL Treatment options for patients with cancer continue to expand, providing
More informationLIVER CANCER AND TUMOURS
LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationAnalysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation *
Journal of Hepatology 44 (2006) 902 909 www.elsevier.com/locate/jhep Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation * Claudio
More informationTreatment of Hepatic Neoplasm
I. Policy University Health Alliance (UHA) will reimburse for treatment of hepatic neoplasm outside of systemic chemotherapy alone when determined to be medically necessary and within the medical criteria
More informationClinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations. Chapter. Grade. CQ No. 1 Interferon Therapy
Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations Chapter Chapter 1 Prevention Sectio n CQ No. 1 Interferon Therapy Clinical Question 1 Does interferon
More informationNATURAL HISTORY OF HEPATOCELLULAR CARCINOMA AND EFFECTS OF TREATMENTS
DOTTORATO DI RICERCA IN BIOPATOLOGIA XXIII CICLO NATURAL HISTORY OF HEPATOCELLULAR CARCINOMA AND EFFECTS OF TREATMENTS Ph. D. Candidate Dr. Giuseppe Cabibbo Tutor Prof. Antonio Craxì (MED 012) Coordinator
More informationNew Data Supporting Modified RECIST (mrecist) for Hepatocellular Carcinoma. Running Title: Modified RECIST (mrecist) for Hepatocellular Carcinoma
New Data Supporting Modified RECIST (mrecist) for Hepatocellular Carcinoma Running Title: Modified RECIST (mrecist) for Hepatocellular Carcinoma Riccardo Lencioni Author s Affiliation: Division of Diagnostic
More informationHepatocellular Carcinoma (HCC)
Abhishek Vadalia Introduction Chemoembolization is being used with increasing frequency in the treatment of solid hepatic tumors such as Hepatocellular Carinoma (HCC) & rare Cholangiocellular Carcinoma
More informationLIVER TUMORS PROFF. S.FLORET
LIVER TUMORS PROFF. S.FLORET NEOPLASM OF LIVER PRIMARY 1)BENIGN 2)MALIGNANT METASTATIC/SECONDARY LIVER Primary Liver Cancer the Second Killer among tumors high morbidity and mortality(20.40/100,000) etiology
More informationScreening for hepatocellular carcinoma: survival benefit and cost-effectiveness
Review Annals of Oncology 14: 1463 1467, 2003 DOI: 10.1093/annonc/mdg400 Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness M.-F. Yuen & C.-L. Lai* Department of Medicine,
More informationOptimal imaging surveillance schedules after liver directed therapy for hepatocellular carcinoma
Optimal imaging surveillance schedules after liver directed therapy for hepatocellular carcinoma F. Edward Boas, MD, PhD; Bao Do, MD; John D. Louie, MD; Nishita Kothary, MD; Gloria L. Hwang, MD; William
More informationManagement of Hepatocellular
Clinician s Guide version 08-05-09 Management of Hepatocellular Carcinoma (HCC) U.S. Department of Veterans Affairs Veterans Health Administration VA Hepatitis C Resource Center Program & VA National Clinical
More informationFocal Treatment of Liver Metastasis. Bjørn Skjoldbye The Gastro Unit Herlev Hospital
Focal Treatment of Liver Metastasis Bjørn Skjoldbye The Gastro Unit Herlev Hospital The Classic approach: Liver metastasis CRC Resectable? Operable? Chemotherapy Surgery Potential cureable disease Liver
More informationHepatocellular carcinoma: Algorithms of diagnosis and options of therapy
Hepatocellular carcinoma: Algorithms of diagnosis and options of therapy Alejandro Forner BCLC Group. Liver Unit. Hospital Clinic. University of Barcelona Pathogenesis and Clinical Practice in Gastroenterology
More informationTHE SECOND VERSION of Evidence-based Clinical
bs_bs_banner doi: 10.1111/hepr.12464 Special Report Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines) Norihiro
More informationDiagnosis, staging and treatment of hepatocellular carcinoma
Brazilian Hepatocellular Journal carcinoma of Medical and Biological Research (2004) 37: 1689-1705 ISSN 0100-879X Review 1689 Diagnosis, staging and treatment of hepatocellular carcinoma A.V.C. França
More informationSBRT (Elekta), 45 Gy in fractions of 3 Gy 3x/week for 5 weeks (N=22) vs.
Uitgangsvraag 6: Wat is de plaats van stereotactische radiotherapiebehandeling (SBRT) bij HCC patiënten? Primaire studies I Study ID II Method III Patient characteristics IV Intervention(s) V Results primary
More informationHepatocellular Carcinoma: A Guide to Screening and Diagnosis
February 2012 Hepatocellular Carcinoma: A Guide to Screening and Diagnosis Reid Merryman, Harvard Medical School Year III Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationCANCER OF THE LIVER HEPATOCELLULAR CARCINOMA
CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA WHAT IS CANCER OF THE LIVER? Hepatocellular carcinoma is the most common form and it comes from the main type of liver cell, the hepatocyte. About 3 out 4
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationManagement of Patients with Recurrent Hepatocellular Carcinoma Following Living Donor Liver Transplantation: A Single Center Experience
Management of Patients with Recurrent Hepatocellular Carcinoma Following Living Donor Liver Transplantation: A Single Center Experience Y. Gunay, N. Guler, M. Akyildiz, O. Yaprak, M. Dayangac, Y. Yuzer,
More informationAntonio Rampoldi Struttura Complessa di Radiologia Interventistica Azienda Ospedale Niguarda Ca Granda, Milano. Terminology
Biophysical principles and clinical applications of MRgFUS Alberto Torresin Struttura Complessa di Fisica Sanitaria Azienda, Milano Università degli Studi di Milano Dip. di Fisica Antonio Rampoldi Struttura
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationMINIMALLY INVASIVE THERMAL THERAPY FOR CANCER TREATMENT BY USING THIN COAXIAL ANTENNAS
MINIMALLY INVASIVE THERMAL THERAPY FOR CANCER TREATMENT BY USING THIN COAXIAL ANTENNAS K. Ito 1, K. Saito 1, T. Taniguchi 2, S. Okabe 2, and H. Yoshimura 1 1 Faculty of Engineering, Chiba University, Chiba,
More informationPredictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer
Surg Endosc (2005) 19: 710 714 DOI: 10.1007/s00464-004-8815-z Ó Springer Science+Business Media, Inc. 2005 Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer
More informationFAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
More informationTreatment options in hepatocellular carcinoma today
Scandinavian Journal of Surgery 100: 22 29, 2011 Treatment options in hepatocellular carcinoma today T. Livraghi 1, H. Mäkisalo 2, P.-D. Line 3 1 Interventional Radiology Department, Istituto Clinico Humanitas,
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma GI Practice Guideline Michael Sanatani, MD, FRCPC (Medical Oncologist) Walter Kocha, MD, FRCPC (Medical Oncologist) Approval Date: October 2006 This guideline is a statement of
More informationChing-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationOncologist. The. Current Approaches to the Treatment of Early Hepatocellular Carcinoma. The Oncologist 2010;15(suppl 4):34 41 www.theoncologist.
The Oncologist Current Approaches to the Treatment of Early Hepatocellular Carcinoma SHENG-LONG YE, a TADATOSHI TAKAYAMA, b JEFF GESCHWIND, c JORGE A. MARRERO, d JEAN-PIERRE BRONOWICKI e a Liver Cancer
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationCase Study in the Management of Patients with Hepatocellular Carcinoma
Management of Patients with Viral Hepatitis, Paris, 2004 Case Study in the Management of Patients with Hepatocellular Carcinoma Eugene R. Schiff This 50-year-old married man with three children has a history
More informationTreatment Advances for Liver Cancer
Treatment Advances for Liver Cancer Guest Expert: Wasif, MD Associate Professor of Medical Oncology Mario Strazzabosco, MD Professor of Internal Medicine, Digestive Diseases www.wnpr.org www.yalecancercenter.org
More informationHepatocellular carcinoma (HCC) is the sixth. Loco-Regional Treatment of Hepatocellular Carcinoma. Riccardo Lencioni
Loco-Regional Treatment of Hepatocellular Carcinoma Riccardo Lencioni Loco-regional treatments play a key role in the management of hepatocellular carcinoma (HCC). Image-guided tumor ablation is recommended
More informationName of Policy: Locoregional Therapies for Hepatocellular Carcinoma and Metastatic Liver Carcinoma and Metastatic Carcinoid Tumors of the Liver
Name of Policy: Locoregional Therapies for Hepatocellular Carcinoma and Metastatic Liver Carcinoma and Metastatic Carcinoid Tumors of the Liver Policy #: 070 Latest Review Date: September 2015 Category:
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationMoving Beyond RECIST
Moving Beyond RECIST Ihab R. Kamel, M.D., Ph.D. ikamel@jhmi.edu Associate Professor Clinical Director, MRI Department of Radiology The Johns Hopkins University School of Medicine Outline Standard measures
More informationLaser Thermal Ablation of Small Hepatocellular Carcinoma
Claudio M. Pacella, MD Giancarlo Bizzarri, MD Fabrizio Magnolfi, MD Piero Cecconi, MD Bruno Caspani, MD Vincenzo Anelli, MD Antonio Bianchini, MD Dario Valle, MD Sara Pacella, MD Guglielmo Manenti, MD
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Measure #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationMesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology
MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image
More informationThe Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative Resection
Yonsei Medical Journal Vol. 47, No. 1, pp. 105-112, 2006 The Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative Resection Jae Gil Lee, 1,2 Chang Mu Kang, 1 Joon Seong Park,
More informationDiagnosis and Treatment of Hepatocellular Carcinoma
GASTROENTEROLOGY 2008;134:1752 1763 Diagnosis and Treatment of Hepatocellular Carcinoma Hashem B. El Serag* Jorge A. Marrero Lenhard Rudolph K. Rajender Reddy *Section of Gastroenterology and Hepatology,
More informationPrimary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
More informationCMS does not have a National Coverage Determination for transarterial chemoembolization for primary liver cancer.
Subject: Transarterial Chemoembolization (TACE) for Primary Liver Hepatocellular Carcinoma (HCC) Guidance Number: MCG-120 Revision Date(s): Original Effective Date: 10/31/2012 Medical Coverage Guidance
More informationSafety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
1628 Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis ALESSANDRO FEDERICO 1*, MICHELE ORDITURA 2*, GAETANO COTTICELLI 1, ILARIO DE SIO
More informationWhat is liver cancer?
Liver Cancer What is liver cancer? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines LIVER CANCER: A GUIDE FOR PATIENTS
More informationLeading the Way to Treat Liver Cancer
Leading the Way to Treat Liver Cancer Guest Expert: Sukru, MD Professor of Transplant Surgery Mario Strazzabosco, MD Professor of Internal Medicine www.wnpr.org www.yalecancercenter.org Welcome to Yale
More informationSmoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
More informationSelection Criteria for Hepatectomy in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus
ANNALS OF SURGERY Vol. 233, No. 3, 379 384 2001 Lippincott Williams & Wilkins, Inc. Selection Criteria for Hepatectomy in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus Masami Minagawa,
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationPRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology
PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI
More informationUK Guidelines for the management of suspected hepatocellular carcinoma (HCC) in adults
UK Guidelines for the management of suspected hepatocellular carcinoma (HCC) in adults SD Ryder DM FRCP Consultant Hepatologist Queens Medical Centre Nottingham University Hospitals NHS Trust Wolfson Digestive
More informationCatheter Embolization and YOU
Catheter Embolization and YOU What is catheter embolization? Embolization therapy is a minimally invasive (non-surgical) treatment that occludes or blocks one or more blood vessels or vascular channels
More informationNon-coronary Brachytherapy
Non-coronary Brachytherapy I. Policy University Health Alliance (UHA) will reimburse for non-coronary brachytherapy when it is determined to be medically necessary and when it meets the medical criteria
More informationHepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy
REVIEW Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy F.A.L.M. Eskens 1 *, K.J. van Erpecum 5, K.P. de Jong 7, O.M. van Delden 8, H.J. Klumpen 9, C. Verhoef 2, P.L.M.
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationHepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
More informationLocoregional Treatment of Hepatocellular Carcinoma. Cory Johnston and Sung Cho HPB Surgery Fellows Providence Portland, Oregon
Locoregional Treatment of Hepatocellular Carcinoma Cory Johnston and Sung Cho HPB Surgery Fellows Providence Portland, Oregon Hepatocellular Carcinoma The 3 rd most common cause of cancer- related death
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationTreatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies
Cancer Treatment Reviews (2006) 32, 594 606 available at www.sciencedirect.com journal homepage: www.elsevierhealth.com/journals/ctrv TUMOUR REVIEW Treatment outcomes for hepatocellular carcinoma using
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationUCLA Asian Liver Program
CLA Program Update Program Faculty Myron J. Tong, PhD, MD Professor of Medicine Hepatology Director, Asian Liver Program Surgery Ronald W. Busuttil, MD, PhD Executive Chair Department of Surgery Director,
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationEvolution of Barrett s esophagus
Endoscopic Treatment and Surveillance of Esophageal Cancer: GI Perspective Charles J. Lightdale, MD Columbia University New York, NY Evolution of Barrett s esophagus Squamous esophagus Chronic inflammation
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationHepatocellular Cancer: A Guide for the Internist
The American Journal of Medicine (2007) 120, 194-202 REVIEW AJM Theme Issue: Gastroenterology Hepatocellular Cancer: A Guide for the Internist Sameer Parikh, MD, David Hyman, MD, MPH Department of Medicine,
More informationYttrium-90 Radioembolization
Yttrium-90 Radioembolization Yttrium-90 radioembolization is generally used as a palliative therapy for selected patients with unresectable tumors of the liver including: Metastatic tumors from colorectal
More informationMachine learning of patient similarity: a case study on predicting survival in cancer patient after locoregional chemotherapy.
Title Machine learning of patient similarity: a case study on predicting survival in cancer patient after locoregional chemotherapy Author(s) Chan, LWC; Chan, T; Cheng, LF; Mak, WS Citation The 2010 IEEE
More informationGuidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults
iii1 GUIDELINES Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults S D Ryder... Gut 2003;52(Suppl III):iii1 iii8 1.0 FOREWORD This document, on the diagnosis and treatment
More informationLiver Transplantation in Patients with Hepatocellular Carcinoma Across Milan Criteria
LIVER TRANSPLANTATION 14:272-278, 2008 ORIGINAL ARTICLE Liver Transplantation in Patients with Hepatocellular Carcinoma Across Milan Criteria J. Ignacio Herrero, 1 Bruno Sangro, 1 Fernando Pardo, 2 Jorge
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationNovel Surgery for Inoperable Brain Tumors. A Patient Guide to NeuroBlate
Novel Surgery for Inoperable Brain Tumors A Patient Guide to NeuroBlate rose ella burkhardt brain tumor and neuro-oncology center Pioneering a Promising Surgical Treatment A brain tumor diagnosis is overwhelming
More informationRecent Progress in Understanding, Diagnosing, and Treating Hepatocellular Carcinoma
Current Treatment Paradigms in Hepatocellular Carcinoma Recent Progress in Understanding, Diagnosing, and Treating Hepatocellular Carcinoma Mary Maluccio, MD, MPH 1 ; Anne Covey, MD 2 Hepatocellular carcinoma
More informationYour Guide to Express Critical Illness Insurance Definitions
Your Guide to Express Critical Illness Insurance Definitions Your Guide to EXPRESS Critical Illness Insurance Definitions This guide to critical illness definitions will help you understand the illnesses
More informationIII. Cell destruction by freezing and cryoprobe development
III. Cell destruction by freezing and cryoprobe development 1 WHAT IS CRYOSURGERY? Cryoprobe Surface iceball formation Ice-ball Cryoprobe Cryosurgery of liver (Angular insertion) Cryosurgery of liver (Vertical
More informationclinical practice guidelines
Annals of Oncology 21 (Supplement 5): v59 v64, 2010 doi:10.1093/annonc/mdq166 Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up S. Jelic 1 & G. C. Sotiropoulos
More informationGreater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 6
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 6 Contents 6. Hepatocellular carcinoma 64 6.1. Introduction: 65 6.2.
More informationAASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma Jordi Bruix 1 and Morris Sherman 2 Preamble These recommendations provide a data-supported approach to the diagnosis, staging and treatment
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
More informationInnovations in Kidney Cancer
Innovations in Kidney Cancer Guest Expert: Harriet, MD Associate Professor of Medical Oncology Edward, MD Assistant Professor of Surgical Urology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationClinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto
Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More information